Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EZH2 | Q15910 | 18/20 | 0.61 |
| ▸ | EED | O75530 | 4/20 | 0.49 |
| ▸ | RBBP4 | Q09028 | 4/20 | 0.49 |
| ▸ | SUZ12 | Q15022 | 4/20 | 0.49 |
| ▸ | RBBP7 | Q16576 | 4/20 | 0.49 |
| ▸ | KDM5B | Q9UGL1 | 2/20 | 0.47 |
| ▸ | AEBP2 | Q6ZN18 | 2/20 | 0.47 |
| ▸ | EZH1 | Q92800 | 2/20 | 0.47 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.47 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12683928 | 0.91 | EZH2 (0.73) | EZH2EEDRBBP4SUZ12RBBP7 | |
| SCHEMBL12684127 | 0.88 | EZH2 (0.61) | EZH2EEDRBBP4SUZ12RBBP7 | |
| SCHEMBL12684301 | 0.87 | EZH2 (0.55) | EZH2EEDRBBP4SUZ12RBBP7 | |
| SCHEMBL12684042 | 0.85 | EZH2 (0.81) | EZH2EEDRBBP4SUZ12RBBP7 | |
| SCHEMBL15490723 | 0.84 | EZH2 (0.86) | EZH2EEDRBBP4SUZ12RBBP7 | |
| SCHEMBL20170042 | 0.84 | EZH2 (0.63) | EZH2EEDRBBP4SUZ12RBBP7 | |
| SCHEMBL12499854 | 0.83 | EZH2 (0.85) | EZH2EEDRBBP4SUZ12RBBP7 | |
| SCHEMBL21418331 | 0.83 | EZH2 (0.45) | EZH2EEDRBBP4SUZ12RBBP7 | |
| SCHEMBL12684097 | 0.81 | EZH2 (0.56) | EZH2EEDRBBP4SUZ12RBBP7 | |
| SCHEMBL12684194 | 0.80 | EZH2 (0.67) | EZH2EEDRBBP4SUZ12RBBP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3323820-B1 | SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS | EPIZYME INC (US) | 2023-05-10 | — | — | EP | disclosed |
| US-20200317643-A1 | SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS | Epizyme, Inc. | 2020-10-08 | — | — | US | disclosed |
| US-20190300502-A1 | SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS | Epizyme, Inc. | 2019-10-03 | — | — | US | disclosed |
| US-10273223-B2 | Substituted 6,5-fused bicyclic heteroaryl compounds | Epizyme, Inc. (US) | 2019-04-30 | — | — | US | disclosed |
| US-20180072702-A1 | SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS | Epizyme, Inc. (US) | 2018-03-15 | — | — | US | disclosed |
| US-20180072702-A1 | SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS | Epizyme, Inc. (US) | 2018-03-15 | — | — | US | disclosed |
| EP-2681216-B1 | SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS | EPIZYME INC (US) | 2017-09-27 | — | — | EP | disclosed |
| US-9637472-B2 | Substituted 6,5-fused bicyclic heteroaryl compounds | Epizyme, Inc. (US) | 2017-05-02 | — | — | US | disclosed |
| US-9637472-B2 | Substituted 6,5-fused bicyclic heteroaryl compounds | Epizyme, Inc. (US) | 2017-05-02 | — | — | US | disclosed |
| US-9206157-B2 | Substituted 6,5-fused bicyclic heteroaryl compounds | Epizyme, Inc. (US) | 2015-12-08 | — | — | US | disclosed |
| US-9206157-B2 | Substituted 6,5-fused bicyclic heteroaryl compounds | Epizyme, Inc. (US) | 2015-12-08 | — | — | US | disclosed |
| US-20150266854-A1 | Substituted 6,5-Fused Bicyclic Heteroaryl Compounds | Epizyme, Inc. | 2015-09-24 | — | — | US | disclosed |
| US-20150266854-A1 | Substituted 6,5-Fused Bicyclic Heteroaryl Compounds | Epizyme, Inc. | 2015-09-24 | — | — | US | disclosed |
| US-20150065483-A1 | Substituted 6,5-Fused Bicyclic Heteroaryl Compounds | Epizyme, Inc. | 2015-03-05 | — | — | US | disclosed |
| US-20150065483-A1 | Substituted 6,5-Fused Bicyclic Heteroaryl Compounds | Epizyme, Inc. | 2015-03-05 | — | — | US | disclosed |
| US-8962620-B2 | Substituted 6,5-fused bicyclic heteroaryl compounds | Epizyme, Inc. (US) | 2015-02-24 | — | — | US | disclosed |
| US-8962620-B2 | Substituted 6,5-fused bicyclic heteroaryl compounds | Epizyme, Inc. (US) | 2015-02-24 | — | — | US | disclosed |
| US-20140057891-A1 | Substituted 6,5-Fused Bicyclic Heteroaryl Compounds | Epizyme, Inc. (US) | 2014-02-27 | — | — | US | disclosed |
| US-20140057891-A1 | Substituted 6,5-Fused Bicyclic Heteroaryl Compounds | Epizyme, Inc. (US) | 2014-02-27 | — | — | US | disclosed |
| WO-2012118812-A2 | SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS | Epizyme, Inc. (US) | 2012-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.